X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (387) 387
middle aged (195) 195
oncology (179) 179
female (176) 176
male (167) 167
adult (163) 163
hematology (143) 143
aged (142) 142
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (121) 121
chronic myelogenous leukemia (118) 118
chronic myeloid-leukemia (116) 116
imatinib mesylate (89) 89
human necessities (86) 86
hygiene (86) 86
medical or veterinary science (86) 86
preparations for medical, dental, or toilet purposes (86) 86
index medicus (84) 84
chronic myeloid leukemia (82) 82
prognosis (82) 82
antineoplastic agents - therapeutic use (81) 81
benzamides (81) 81
leukemia, myelogenous, chronic, bcr-abl positive - genetics (77) 77
treatment outcome (74) 74
philadelphia chromosome (71) 71
leukemia, myelogenous, chronic, bcr-abl positive - therapy (60) 60
therapy (60) 60
leukemia, myelogenous, chronic, bcr-abl positive - pathology (58) 58
leukemia (56) 56
chemistry (55) 55
heterocyclic compounds (55) 55
interferon-alpha - therapeutic use (55) 55
metallurgy (55) 55
organic chemistry (55) 55
piperazines - therapeutic use (55) 55
pyrimidines - therapeutic use (55) 55
cancer (48) 48
acyclic or carbocyclic compounds (47) 47
specific therapeutic activity of chemical compounds ormedicinal preparations (47) 47
aged, 80 and over (46) 46
adolescent (44) 44
remission induction (44) 44
acute lymphoblastic-leukemia (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
blast crisis (41) 41
research (41) 41
interferon-alpha (40) 40
drug therapy (39) 39
animals (38) 38
fusion proteins, bcr-abl - genetics (38) 38
philadelphia-chromosome (38) 38
bcr-abl (37) 37
bone-marrow transplantation (36) 36
follow-up studies (36) 36
medicine, general & internal (35) 35
care and treatment (34) 34
protein-tyrosine kinases - antagonists & inhibitors (34) 34
survival (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - mortality (33) 33
survival analysis (32) 32
abl tyrosine kinase (30) 30
cytogenetic responses (30) 30
dose-response relationship, drug (30) 30
expression (29) 29
mice (29) 29
protein kinase inhibitors - therapeutic use (29) 29
survival rate (29) 29
antineoplastic agents - adverse effects (25) 25
cells (25) 25
drug administration schedule (24) 24
imatinib (24) 24
interferon (24) 24
tyrosine kinase inhibitor (24) 24
bone marrow - pathology (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (23) 23
antineoplastic agents - administration & dosage (22) 22
article (22) 22
colony-stimulating factor (22) 22
drug resistance, neoplasm (22) 22
leukemia, myelogenous, chronic, bcr-abl positive - blood (22) 22
pyrimidines - administration & dosage (22) 22
pyrimidines - adverse effects (22) 22
tumor cells, cultured (22) 22
disease progression (21) 21
genetic aspects (21) 21
inhibitor (21) 21
interferon type i - therapeutic use (21) 21
myelofibrosis (21) 21
time factors (21) 21
abridged index medicus (20) 20
chronic granulocytic-leukemia (20) 20
cytogenetic response (20) 20
health aspects (20) 20
hematology, oncology and palliative medicine (20) 20
mutation (20) 20
primary myelofibrosis - drug therapy (20) 20
recombinant proteins (20) 20
risk factors (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
bone marrow transplantation (19) 19
chronic-phase (19) 19
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (838) 838
French (32) 32
German (15) 15
Chinese (7) 7
Portuguese (4) 4
Spanish (4) 4
Danish (2) 2
Korean (2) 2
Slovenian (2) 2
Greek (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 7, pp. 789 - 796
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 24, pp. 2531 - 2541
Journal Article
1995, ISBN 1853172162, ix, 445
Book
1995, Cancer treatment and research, ISBN 0792336364, Volume 80, xii, 387
Book
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2009, pp. 461 - 476
Given its relative rarity, it may at first seem surprising that chronic myeloid leukemia (CML) has garnered so much attention over the last decade. Yet, the... 
Piperazines - administration & dosage | Drugs, Investigational - pharmacology | Epigenesis, Genetic | Humans | Neoplasm Proteins - physiology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Salvage Therapy | Drugs, Investigational - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Drug Delivery Systems | Dose-Response Relationship, Drug | Drug Design | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Biological Transport - drug effects | Piperazines - pharmacokinetics | Neoplasm Proteins - genetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Kinase Inhibitors - pharmacokinetics | Protein Kinase Inhibitors - classification | Pyrimidines - administration & dosage | Piperazines - therapeutic use | Signal Transduction - genetics | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - physiology | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - pharmacokinetics | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Benzamides | Drug Resistance, Neoplasm - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 612 - 621
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | KINASE DOMAIN MUTATIONS | DIAGNOSED CHRONIC-PHASE | TYROSINE KINASE | INTERNATIONAL-WORKING-GROUP | FOLLOW-UP | CLINICAL RESISTANCE | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 799 - 807
Journal Article
Nature Genetics, ISSN 1061-4036, 02/2013, Volume 45, Issue 2, pp. 180 - 185
Journal Article